Production (Stage)
ProQR Therapeutics N.V.
PRQR
$1.91
$0.126.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.61M | -9.92M | -8.91M | -2.90M | -8.31M |
| Total Depreciation and Amortization | 713.50K | 715.30K | 756.40K | 765.30K | 750.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 341.00K | -182.30K | 710.20K | 364.90K | 1.15M |
| Change in Net Operating Assets | -7.07M | -578.80K | 1.23M | -4.97M | -10.01M |
| Cash from Operations | -16.63M | -9.96M | -6.22M | -6.73M | -16.43M |
| Capital Expenditure | -235.70K | -141.80K | -314.40K | -287.40K | -794.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -2.83M | 18.69M | -- | -18.45M |
| Cash from Investing | -235.70K | -2.97M | 18.38M | -287.40K | -19.25M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -567.00K | -253.00K | -454.00K | -294.00K | -581.00K |
| Issuance of Common Stock | 67.00K | 71.68M | 1.00K | 12.00K | 162.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -526.20K | 76.14M | -498.00K | -303.50K | -454.90K |
| Foreign Exchange rate Adjustments | -496.70K | 760.00K | -190.20K | 66.70K | 77.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.88M | 63.97M | 11.47M | -7.26M | -36.05M |